Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

hagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and GI ulcer). Drug hypersensitivity reactions were reported in <0.1% of patients receiving PRADAXA.

Other Measures Evaluated
In the pivotal trial, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA (0.7 per 100 patient-years for 150 mg dose) than in those who received warfarin (0.6).

Click here for full PRADAXA prescribing information and medication guide.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expen
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... TOKYO , July 28, 2014  ImaginAb, ... Roger Crystal , MD as Vice President of ... Global Business Development Product Acquisition & Licensing team at ... developing business strategy and partnerships in the precision medicine ... partner with biotechnology and pharmaceutical companies across the spectrum ...
(Date:7/28/2014)... July 28, 2014   Cardioxyl Pharmaceuticals, Inc. ... demonstrating that CXL-1427, a novel potential treatment for acute ... volunteers. The company has now initiated dosing of hospitalized ... clinical trial designed to further evaluate the drug,s safety ... The Phase I clinical trial evaluated the safety ...
(Date:7/28/2014)... and NEW PROVIDENCE, N.J. , July ... are invited to meet with Linde,s Healthcare division ... to be held at McCormick Place in ... "Hospitals demand nothing less than complete confidence in ... , Linde,s Healthcare Segment manager. "Linde understands the importance ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Sept. 1 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Insert From Carl Zeiss Meditec -- CLERMONT-FERRAND, France, September 1, 2010 ... ... lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:Yongye International Announces RMB 400 Million Revolving Credit Facilities 2Yongye International Announces RMB 400 Million Revolving Credit Facilities 3Yongye International Announces RMB 400 Million Revolving Credit Facilities 4Yongye International Announces RMB 400 Million Revolving Credit Facilities 5Yongye International Announces RMB 400 Million Revolving Credit Facilities 6Yongye International Announces RMB 400 Million Revolving Credit Facilities 7Yongye International Announces RMB 400 Million Revolving Credit Facilities 8French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 2French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 3French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 4French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 5French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 6French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 7
(Date:7/28/2014)... According to a new market ... II-VI, IV-IV, sapphire), Deposition Technology (CVD, MBE, HVPE, ... Application, and Geography-2013-2020", published by MarketsandMarkets, the market ... 12.63% from 2014 to 2020 and reach $104.55 ... tables and 88 figures spread through 342 pages ...
(Date:7/28/2014)... A St. Jude Children’s Research Hospital ... childhood cancer more than doubled their risk of developing ... follow a heart-healthy lifestyle. The results appear in the ... percent of the 1,598 adult survivors of childhood cancer ... for health risk factors like high blood pressure, abdominal ...
(Date:7/28/2014)... Over the years, many adolescents have been forced to ... pain in their knees. A new PhD study involving ... often carries on: , "We can see from the ... ages of 12 and 19 experience problems with pain ... daily knee pain in the front of the knee," ...
(Date:7/28/2014)... SOPHIE has evaluated the relationship between the type ... in Europe. The results show that countries with ... countries with contradictory policies (Eastern Europe), present higher ... health than men. Health inequalities are especially remarkable ... 27% higher risk of having poor health compared ...
(Date:7/28/2014)... Australia (PRWEB) July 28, 2014 What ... a happier lifestyle can often be a struggle that ... channel, psychic and medium, Lynette Leckie-Clark provides simple how-to ... book “The Magic of You.” With inspiring spiritual affirmations ... you can find empowerment, confidence and motivation for everyday ...
Breaking Medicine News(10 mins):Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 2Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 3Health News:Compound Semiconductor Market by Type (III-V, II-VI, IV-IV, sapphire), Deposition Technology, Product Worth $104.55 Billion in 2020 - New Report by MarketsandMarkets 4Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 2Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 3Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 4Health News:Many people never grow out of their growing pains 2Health News:Gender inequalities in health: A matter of policies 2Health News:Be Empowered to Achieve Happiness from New Book "The Magic of You" 2
... prime minister Mr. Girija Prasad Koirala, which was scheduled to ... health, but his party sources informed that his condition is ... King Gyanendra Thursday evening, was scheduled to be administered the ... Friday, two hours before parliament convenes after four long years. ...
... groups are demanding the government for new and better breast ... National Institute// for Clinical Excellence rejected two new breast cancer ... the patient groups who were campaigning for access to every ... cheaper medicines in clinical trials. The two drugs were docetaxel ...
... eight-year pupil in southwest China's Sichuan province was confirmed ... ministry said Thursday//. ,The girl, surnamed Sun, from ... of fever and pneumonia April 16. She was being ... ,Investigators reported that poultry deaths occurred in ...
... A study by Dutch researchers suggests that eating foods ... down the risk of developing motor neurone disease by ... Utrecht in the Netherlands report their findings in the ... tracked 132 patients who had potential or definite amyotrophic ...
... offered to GPs after negative publicity over the move resulted ... were responsible for NHS deficits. ,The new GP ... increased by 25 percent. BMA's Dr Mary Church defended the ... being as much as ?100,000 was true for GPs in ...
... of asthma symptoms in people with allergic asthma. Dust mites, ... important cause of allergic reactions. //The proteins present in the ... similar to that of asthma. Hence the development of the ... ,Cytos is a Swiss vaccine company which manufactures this vaccine. ...
Cached Medicine News:
... Anion traces: chloride (Cl) ≤ 500 mg/kg sulfate (SO ... 500 mg/kg Cd ≤ 5 mg/kg Co ≤ 5 ... Fe ≤ 10 mg/kg K ≤ 5 mg/kg Mg ... 2000 mg/kg Ni ≤ 5 mg/kg Pb ≤ 5 ...
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
Inquire...
Medicine Products: